Monopar Therapeutics
MNPR
13 hedge funds and large institutions have $657K invested in Monopar Therapeutics in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
44% more funds holding
Funds holding: 9 → 13 (+4)
0.01% more ownership
Funds ownership: 0.32% → 0.32% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
32% less capital invested
Capital invested by funds: $964K → $657K (-$307K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$13.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.6K |
| 3 |
FCA
FinTrust Capital Advisors
Greenville,
South Carolina
|
+$2.22K |
| 4 |
BlackRock
New York
|
+$1.38K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$1.86K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $321K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $126K | – | – | – |
|
|
3
Northern Trust
Chicago,
Illinois
| $115K | -$1.86K | -84 | -1% |
|
|
4
BlackRock
New York
| $46K | +$1.38K | +62 | +2% |
|
5
Morgan Stanley
New York
| $13K | – | – | – |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $13K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $10K | +$13.6K | +613 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $8K | +$10.6K | +480 | New |
|
|
APA
9
American Portfolios Advisors
Holbrook,
New York
| $2.25K | – | – | – |
|
|
FCA
10
FinTrust Capital Advisors
Greenville,
South Carolina
| $2K | +$2.22K | +100 | New |
|
11
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
12
Bank of America
Charlotte,
North Carolina
| – | +$22 | +1 | New |
|
MNPR Hedge Fund Activity: Q4 2021 in Review
13 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2021, worth a combined $657K — down 32% from $964K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MNPR positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $13.6K. The largest seller was Northern Trust, cutting an estimated $1.86K.
- 13 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2021, up from 9 in Q3 2021.
- Funds reported $657K of Monopar Therapeutics stock for Q4 2021, down 32% quarter-over-quarter.
- 4 funds opened new Monopar Therapeutics positions in Q4 2021 and 0 closed out, a net change of +4 holders.
- The largest Monopar Therapeutics buyer in Q4 2021 was UBS Group, an estimated $13.6K added.
- The largest Monopar Therapeutics seller in Q4 2021 was Northern Trust, an estimated $1.86K sold.
Based on aggregated 13F filings for Q4 2021.